• Dr. Amanullah Khan MD

TAGRISSO- New Indications for Non Small Cell Lung Cancer!


Adjuvant TAGRISSO was approved with breakthrough therapy designation status as adjuvant therapy after tumor resection in adult patients with non‑small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test—this is unparalleled news for resectable EGFRm NSCLC patients.



To see if this mediation is right for you, please contact our office at 972-548-9690 to speak to one of our physicians.

Office Hours:

Monday - Friday: 8:00 am - 4:30 pm

Now offering Telemedicine 

New Patient?

Have an upcoming appointment? Please fill out this online assessment to save time on your visit.

Locations

4201 Medical Center Drive, Suite 180

McKinney, TX  75069

Phone: (972) 548-9690

Need to refill a Rx?

Running low on your prescription? Fill out the online request form. 

2698 N. Galloway, Suite 103

Mesquite, TX 75150

Phone: (972) 686-6646

5948  W. Parker Rd. Suite 100

Plano, TX  75093

Phone: (972) 686-6646

© 2020 CANCER CENTER ASSOCIATES.  ALL RIGHTS RESERVED.  Design by BigMagic.com